IN2014CN01466A - - Google Patents
Info
- Publication number
- IN2014CN01466A IN2014CN01466A IN1466CHN2014A IN2014CN01466A IN 2014CN01466 A IN2014CN01466 A IN 2014CN01466A IN 1466CHN2014 A IN1466CHN2014 A IN 1466CHN2014A IN 2014CN01466 A IN2014CN01466 A IN 2014CN01466A
- Authority
- IN
- India
- Prior art keywords
- amino acids
- seq
- linear
- acid sequence
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An object of the present invention is to provide a monoclonal antibody binding to human XCR1 wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th 11th 12th 13th 14th 16th 17th 22nd 23rd 176th and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161530194P | 2011-09-01 | 2011-09-01 | |
US201261659637P | 2012-06-14 | 2012-06-14 | |
PCT/JP2012/072667 WO2013032032A1 (en) | 2011-09-01 | 2012-08-30 | Anti-human xcr1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN01466A true IN2014CN01466A (en) | 2015-05-08 |
Family
ID=46881120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1466CHN2014 IN2014CN01466A (en) | 2011-09-01 | 2012-08-30 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9371389B2 (en) |
EP (1) | EP2751140B1 (en) |
JP (1) | JP5989096B2 (en) |
KR (1) | KR101767717B1 (en) |
CN (1) | CN103764680B (en) |
AR (1) | AR087749A1 (en) |
AU (1) | AU2012302596B2 (en) |
BR (1) | BR112014004352A2 (en) |
CA (1) | CA2846370C (en) |
ES (1) | ES2684173T3 (en) |
HK (1) | HK1199038A1 (en) |
IL (1) | IL231075A (en) |
IN (1) | IN2014CN01466A (en) |
MX (1) | MX346560B (en) |
MY (1) | MY166152A (en) |
RU (1) | RU2619180C2 (en) |
TW (1) | TWI563004B (en) |
WO (1) | WO2013032032A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10071170B2 (en) | 2013-06-24 | 2018-09-11 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
MX2018001465A (en) * | 2015-08-05 | 2019-01-31 | Acticor Biotech | Novel anti-human gpvi antibodies and uses thereof. |
KR20240046168A (en) | 2017-02-03 | 2024-04-08 | 액티코어 바이오테크 | Inhibition of platelet aggregation using anti-human gpvi antibodies |
WO2018146074A1 (en) | 2017-02-07 | 2018-08-16 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
CN107312092B (en) * | 2017-05-04 | 2020-12-11 | 华南农业大学 | Preparation method and application of polyclonal antibody of epinephelus coioides CCR12 |
US20210130776A1 (en) * | 2017-09-29 | 2021-05-06 | The Broad Institute, Inc. | Methods and compositions for modulating suppression of lymphocyte activity |
US20200354424A1 (en) * | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
JP2022515473A (en) | 2018-12-28 | 2022-02-18 | エフ.ホフマン-ラ ロシュ アーゲー | Peptide-MHC-I-antibody fusion protein for therapeutic use in patients with amplified immune response |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5786210A (en) | 1994-02-08 | 1998-07-28 | Schering Corporation | Mammalian thymokine genes |
AU2001250412A1 (en) * | 2000-03-31 | 2001-10-08 | Ipf Pharmaceuticals Gmbh | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
WO2002059608A2 (en) | 2000-11-29 | 2002-08-01 | Lifespan Biosciences, Inc. | Compositions and methods related to chemokine (c motif) xc receptor 1 (ccxcr1) |
US20050136033A9 (en) | 2002-08-13 | 2005-06-23 | Matthias Mack | Method of treating allergen induced airway disease |
WO2004072646A1 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5) |
EP1698902A1 (en) * | 2005-03-01 | 2006-09-06 | DKFZ Deutsches Krebsforschungszentrum | Use of XCR1 for diagnosing or monitoring of immune tolerance |
CN101293924A (en) | 2007-04-24 | 2008-10-29 | 上海国健生物技术研究院 | Monoclone antibody with combined function epiposition, specificity of osteopontin and in preparing antineoplastic diversion medicaments |
EP2062592A1 (en) * | 2007-11-20 | 2009-05-27 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | System for delivery into a XCR1 positive cell and uses thereof |
WO2010093480A2 (en) | 2009-02-16 | 2010-08-19 | Biolex Therapeutics, Inc. | Humanized anti-cd20 antibodies and methods of use |
-
2012
- 2012-08-30 MX MX2014002078A patent/MX346560B/en active IP Right Grant
- 2012-08-30 ES ES12761822T patent/ES2684173T3/en active Active
- 2012-08-30 BR BR112014004352A patent/BR112014004352A2/en not_active Application Discontinuation
- 2012-08-30 KR KR1020147004507A patent/KR101767717B1/en active IP Right Grant
- 2012-08-30 TW TW101131633A patent/TWI563004B/en not_active IP Right Cessation
- 2012-08-30 CN CN201280041366.2A patent/CN103764680B/en not_active Expired - Fee Related
- 2012-08-30 WO PCT/JP2012/072667 patent/WO2013032032A1/en active Application Filing
- 2012-08-30 AR ARP120103217A patent/AR087749A1/en unknown
- 2012-08-30 JP JP2014509528A patent/JP5989096B2/en not_active Expired - Fee Related
- 2012-08-30 IN IN1466CHN2014 patent/IN2014CN01466A/en unknown
- 2012-08-30 US US14/240,090 patent/US9371389B2/en not_active Expired - Fee Related
- 2012-08-30 CA CA2846370A patent/CA2846370C/en not_active Expired - Fee Related
- 2012-08-30 AU AU2012302596A patent/AU2012302596B2/en not_active Ceased
- 2012-08-30 MY MYPI2014700412A patent/MY166152A/en unknown
- 2012-08-30 EP EP12761822.1A patent/EP2751140B1/en not_active Not-in-force
- 2012-08-30 RU RU2014106832A patent/RU2619180C2/en not_active IP Right Cessation
-
2014
- 2014-02-20 IL IL231075A patent/IL231075A/en active IP Right Grant
- 2014-12-09 HK HK14112359.4A patent/HK1199038A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL231075A0 (en) | 2014-03-31 |
MY166152A (en) | 2018-06-06 |
WO2013032032A1 (en) | 2013-03-07 |
US20140193421A1 (en) | 2014-07-10 |
BR112014004352A2 (en) | 2017-03-21 |
IL231075A (en) | 2017-08-31 |
AU2012302596B2 (en) | 2016-12-01 |
CA2846370A1 (en) | 2013-03-07 |
AR087749A1 (en) | 2014-04-16 |
CN103764680A (en) | 2014-04-30 |
MX346560B (en) | 2017-03-24 |
ES2684173T3 (en) | 2018-10-01 |
NZ621320A (en) | 2015-11-27 |
MX2014002078A (en) | 2014-05-30 |
JP2014527396A (en) | 2014-10-16 |
KR101767717B1 (en) | 2017-08-11 |
AU2012302596A1 (en) | 2014-03-06 |
JP5989096B2 (en) | 2016-09-07 |
US9371389B2 (en) | 2016-06-21 |
EP2751140A1 (en) | 2014-07-09 |
CN103764680B (en) | 2016-11-23 |
TWI563004B (en) | 2016-12-21 |
KR20140054108A (en) | 2014-05-08 |
HK1199038A1 (en) | 2015-06-19 |
CA2846370C (en) | 2019-04-23 |
RU2619180C2 (en) | 2017-05-12 |
TW201311725A (en) | 2013-03-16 |
EP2751140B1 (en) | 2018-05-30 |
RU2014106832A (en) | 2015-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN01466A (en) | ||
JOP20190017A1 (en) | Human cgrp receptor binding antibodies | |
NZ607969A (en) | Cd33 binding agents | |
MX2019011952A (en) | Anti-garp protein and uses thereof. | |
UA111818C2 (en) | ANTIBODY AGAINST CSF-1R | |
MA34524B1 (en) | ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) | |
NZ610267A (en) | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use | |
UA115402C2 (en) | CD3-Binding Molecule Able to Bind to CD3 HUMAN AND NON-HUMAN CD3 | |
MX2019014658A (en) | Humanized antibodies that recognize alpha-synuclein. | |
NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
UA113623C2 (en) | TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR | |
AU2018256498A1 (en) | Antibodies to amyloid beta | |
MX362039B (en) | Anti-il-23 antibodies. | |
UA113609C2 (en) | ANTIGENCY BINDING PROTEIN Binding HUMAN IL-23 | |
NZ601615A (en) | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor | |
MX358224B (en) | Pharmaceutical composition for treatment and/or prevention of liver cancer. | |
UA117901C2 (en) | Antibody variants and uses thereof | |
MX357193B (en) | Anti-alpha synuclein binding molecules. | |
UA107574C2 (en) | Humanized antibody specific to the protofibrillar form of the beta-amyloid peptide | |
MX2016004579A (en) | Tm4sf1 binding proteins and methods of using same. | |
MY160590A (en) | Cd127 binding proteins | |
MX2012002565A (en) | Enhanced protein purification through a modified protein a elution. | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
WO2012006341A8 (en) | Anti-ron antibodies | |
NZ607720A (en) | Peptide or peptide complex binding to 2 integrin and methods and uses involving the same |